Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Intellia Therapeutics to Present at November Healthcare Investor Conferences

GlobeNewswire Thursday, 8 November 2018
CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will participate in the following upcoming healthcare conferences in November:*Tuesday, November 13, 2018
**Credit Suisse Healthcare Conference
*Location: Scottsdale, Arizona
Time: 2:50pm MT (4:50pm ET)

*Thursday, November 15, 2018
**Jefferies London Healthcare Conference
*Location: London, United Kingdom
Time: 12:40pm GMT (7:40am ET)

* Thursday, November 29, 2018
**Barclays Gene Editing and Gene Therapy Summit
*Location: New York, NY
Time: 3:00pm ET

A live webcast of Intellia’s presentations at the Credit Suisse Healthcare Conference and Jefferies London Healthcare Conference will be accessible through the Events and Presentations page of the Investor Relations section of the company’s website at www.intelliatx.com. To access the webcasts, please log on to the Intellia website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Intellia’s website for approximately 14 days following each conference.

*About Intellia Therapeutics
*Intellia Therapeutics is a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course, and through improved cell therapies that can treat cancer and immunological diseases, or can replace patients’ diseased cells. The combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com and follow us on Twitter @intelliatweets.

*Investor Contact:                                          *
Lindsey Trickett
Vice President, Investor Relations
+1 857-285-6211
lindsey.trickett@intelliatx.com

*Media Contact:*
Jennifer Mound Smoter
Senior Vice President, External Affairs & Communications
+1 857-706-1071
jenn.smoter@intelliatx.com
0
shares
ShareTweetSavePostSend
 

You Might Like


Tweets about this


Other recent news in Press Releases

ZincX Resources Reports Voting Results from Its Annual GENERAL and Special MeetingFirmenich in Top 2 Worldwide With CDP Triple 'A' for CLIMATE Change, Water & Forests
AAX is World's First Digital Asset Exchange to be Powered by LONDON Stock Exchange Group TechnologyStart Up Establishments Benefit From Latest No Cost Offer For ezCheckprinting BUSINESS Software
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Contact us  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest